Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433497 | 0.89 | HTT (0.58) | HTTSMN1; SMN2TDP1ALDH1A1LMNA | |
| SCHEMBL9720036 | 0.89 | HTT (0.58) | HTTSMN1; SMN2TDP1ALDH1A1LMNA | |
| SCHEMBL31231738 | 0.87 | GAA (0.62) | SMN1; SMN2TDP1ALDH1A1GAAMAPT | |
| SCHEMBL1586 | 0.87 | GAA (0.62) | SMN1; SMN2TDP1ALDH1A1GAAMAPT | |
| SCHEMBL12111332 | 0.85 | HTT (0.59) | HTTSMN1; SMN2TDP1L3MBTL1FFAR1 | |
| Water SCHEMBL6162445 | 0.84 | GAA (0.59) | SMN1; SMN2TDP1ALDH1A1GAAMAPT | |
| SCHEMBL6621808 | 0.84 | GAA (0.59) | SMN1; SMN2TDP1ALDH1A1GAAMAPT | |
| Hydrochloric Acid SCHEMBL2833772 | 0.84 | GAA (0.59) | SMN1; SMN2TDP1ALDH1A1GAAMAPT | |
| SCHEMBL31058081 | 0.84 | GAA (0.59) | SMN1; SMN2TDP1ALDH1A1GAAMAPT | |
| Hydrochloric Acid SCHEMBL29967262 | 0.84 | GAA (0.59) | SMN1; SMN2TDP1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-7803793-B2 | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-28 | — | — | US | disclosed |
| EP-2089365-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-08-19 | — | — | EP | disclosed |
| US-7504537-B2 | Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008045668-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-17 | — | — | WO | disclosed |
| US-6849732-B2 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1095936-B1 | Intermediates useful for the preparation of metallproteinase inhibitors | AGOURON PHARMA (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030130506-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | AGOURON PHARMACEUTICALS, INC. (US) | 2003-07-10 | — | — | US | disclosed |
| US-6500948-B1 | SUCH AS N-HYDROXY-4-(4-((PYRID-4-YL)OXY)BENZENESULFONYL)-2,2-DIMETHYL-TETRAHYDRO-2H -1,4-THIAZINE-3-CARBOXYLIC ACID | AGOURON PHARMACEUTICALS, INC. | 2002-12-31 | — | — | US | disclosed |
| US-H1992-H1 | INHIBITION OF METALLOPROTEINASES AND TUMOR NECROSIS FACTOR CONVERTASE WHICH DEGRADE PROTEIN COMPONENTS OF EXTRACELLULAR MATRIX | AGOURON PHARMACEUTICALS, INC. | 2001-09-04 | — | — | US | disclosed |
| EP-1095936-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | AGOURON PHARMACEUTICALS, INC. (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6153757-A | A PRODRUG, SALT OR SOLVATE AS ANTITUMOR AGENT AND ENZYME INHIBITOR FOR INHIBITING METALLOPROTEINASES, TUMOR NECROSIS FACTOR | AGOURON PHARMACEUTICALS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-2000063165-A1 | MMP INHIBITOR | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-26 | — | — | WO | disclosed |
| EP-0973748-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5985900-A | TREATING TUMOR GROWTH, INVASION OR METASTASIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CHRONIC DERMAL WOUNDS, CORNEAL ULCERATION, DEGENERATIVE SKIN DISORDERS, MULTIPLE SCLEROSIS, STROKE, ATHEROSCLEROSIS, | AGOURON PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1998050348-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0874830-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998043963-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 1998-10-08 | — | — | WO | disclosed |
| WO-1997020824-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130506-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | MMP9, MMP3, MMP2 | HTT 4631/4885SMN1; SMN2 2927/4885TDP1 2266/4885 |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | HTT 1950/4885SMN1; SMN2 1626/4885TDP1 1647/4885 |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | HTT 1950/4885SMN1; SMN2 1626/4885TDP1 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.